Ovarian stimulation in young adult cancer survivors on targeted cancer therapies

Successful fertility treatments are possible in the context of exposure to anaplastic lymphoma kinase inhibitors, specifically crizotinib, and RANKL antibody, specifically denosumab.

Like Comment

Volume 106, Issue 6, Pages 1475-1478


H. Irene Su, M.D., M.S.C.E., Meghan W. Connell, B.S., Lyudmila A. Bazhenova, M.D.



To describe a clinical approach to and outcomes of IVF in reproductive-aged cancer survivors receiving targeted cancer therapies.


Case report.


Academic fertility preservation program.


The first case is of a female patient with metastatic lung cancer receiving long-term crizotinib, an anaplastic lymphoma kinase inhibitor. The second case is of a female patient with metastatic colon cancer receiving long-term denosumab, a RANKL antibody. Both patients presented desiring fertility.


In vitro fertilization.

Main Outcome Measure(s)

Live birth and embryo banking.


The potential impact of targeted therapy on oocytes and pregnancy was investigated via literature review and pharmaceutical company inquiries. After oncologic, fertility, and psychological counseling, both survivors underwent ovarian stimulation, IVF, and preimplantation genetic screening. One couple achieved live births of dizygotic twins via gestational surrogacy. The second couple froze one euploid blastocyst for future fertility. Both survivors are stable from their cancer standpoints.


Successful fertility treatments are possible in the context of exposure to crizotinib and denosumab.

Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility┬« is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.